Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Osamu Honjo"'
Autor:
Kana Hashimoto, MD, Daisuke Morinaga, MD, Hajime Asahina, MD, PhD, Mina Ishidoya, MD, Hajime Kikuchi, MD, PhD, Hiroshi Yokouchi, MD, PhD, Toshiyuki Harada, MD, PhD, Osamu Honjo, MD, Ryota Shigaki, MD, Taichi Takashina, MD, PhD, Yuka Fujita, MD, PhD, Mamoru Takahashi, MD, PhD, Yasutaka Kawai, MD, Ryotaro Kida, MD, Kenichiro Ito, MD, Noriaki Sukoh, MD, PhD, Ayumu Takahashi, MD, PhD, Fumihiro Hommura, MD, PhD, Yoshihito Ohhara, MD, PhD, Megumi Furuta, MD, PhD, Satoshi Konno, MD, PhD, Yukio Hosomi, MD, PhD, Satoshi Oizumi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100715- (2024)
Introduction: Oligometastasis and oligoprogression (OP) has not been adequately defined in extensive-stage SCLC (ES-SCLC) and may be a good indication for adding local treatment. Therefore, this multicenter study aimed to investigate the prognostic i
Externí odkaz:
https://doaj.org/article/6a9e9af6ebb84315b50bcf56a349d75d
Autor:
Daisuke Morinaga, Hajime Asahina, Shotaro Ito, Osamu Honjo, Hisashi Tanaka, Ryoichi Honda, Hiroshi Yokouchi, Keiichi Nakamura, Kei Takamura, Fumihiro Hommura, Yasutaka Kawai, Kenichiro Ito, Noriaki Sukoh, Keiki Yokoo, Ryo Morita, Toshiyuki Harada, Taichi Takashina, Tomohiro Goda, Hirotoshi Dosaka‐Akita, Hiroshi Isobe, the Hokkaido Lung Cancer Clinical Study Group Trial
Publikováno v:
Cancer Medicine, Vol 12, Iss 10, Pp 11525-11541 (2023)
Abstract Purpose Immune‐checkpoint inhibitors (ICIs) are effective against advanced non‐small cell lung cancer (NSCLC). However, whether the efficacy and safety of ICI treatment in elderly patients are similar to those in younger patients is uncl
Externí odkaz:
https://doaj.org/article/e841a5a350844541b0287c7aee9ab30b
Autor:
Gaku Yamamoto, Hajime Asahina, Osamu Honjo, Toshiyuki Sumi, Atsushi Nakamura, Kenichiro Ito, Hajime Kikuchi, Fumihiro Hommura, Ryoichi Honda, Keiki Yokoo, Yuka Fujita, Satoshi Oizumi, Ryo Morita, Yasuyuki Ikezawa, Hisashi Tanaka, Nozomu Kimura, Takaaki Sasaki, Noriaki Sukoh, Taichi Takashina, Toshiyuki Harada, Hirotoshi Dosaka-Akita, Hiroshi Isobe, the Hokkaido Lung Cancer Clinical Study Group Trial
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line th
Externí odkaz:
https://doaj.org/article/30fdf5599db64195b591b2c71f3f2250
Autor:
Osamu Honjo, Terufumi Kubo, Fumiko Sugaya, Takahiro Nishizaka, Koji Kato, Yoshihiko Hirohashi, Hiroki Takahashi, Toshihiko Torigoe
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)
Abstract Background Immune checkpoint inhibitors (ICIs) have provided more options in the treatment of lung cancer. However, ICIs can cause several unfavorable reactions generally referred to as immune-related adverse effects. Case presentation In th
Externí odkaz:
https://doaj.org/article/c9f505ea2ead4ca18ba92f435e68485d
Autor:
Kengo Umehara, Kaori Yama, Keisuke Goto, Azusa Wakamoto, Tae Hatsuyama, Osamu Honjo, Toyohiro Saikai, Akihisa Fujita, Hideki Sato
Publikováno v:
Cancer Control, Vol 28 (2021)
Introduction: Corticosteroids are used to treat immune-related adverse events (irAEs) associated with nivolumab. However, patients with non-small-cell lung cancer who are administered corticosteroids before the initiation of nivolumab treatment are c
Externí odkaz:
https://doaj.org/article/ecec087538944c1ea8719ec7d92f55e7
Autor:
Hiroshi Yokouchi, Hiroshi Nishihara, Toshiyuki Harada, Toraji Amano, Takayuki Ohkuri, Shigeo Yamazaki, Hajime Kikuchi, Satoshi Oizumi, Hidetaka Uramoto, Fumihiro Tanaka, Masao Harada, Kenji Akie, Fumiko Sugaya, Yuka Fujita, Kei Takamura, Tetsuya Kojima, Mitsunori Higuchi, Osamu Honjo, Yoshinori Minami, Naomi Watanabe, Masaharu Nishimura, Hiroyuki Suzuki, Hirotoshi Dosaka-Akita, Hiroshi Isobe
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
OX40 (CD134) is a co-stimulatory molecule mostly expressed on activated T lymphocytes. Previous reports have shown that OX40 can be an immuno-oncology target and a clinical biomarker for cancers of various organs. In this study, we collected formalin
Externí odkaz:
https://doaj.org/article/18254917a1194ec3b68c770c8b7a5de6
Autor:
Hiroshi Yokouchi, Hiroshi Nishihara, Toshiyuki Harada, Shigeo Yamazaki, Hajime Kikuchi, Satoshi Oizumi, Hidetaka Uramoto, Fumihiro Tanaka, Masao Harada, Kenji Akie, Fumiko Sugaya, Yuka Fujita, Kei Takamura, Tetsuya Kojima, Mitsunori Higuchi, Osamu Honjo, Yoshinori Minami, Naomi Watanabe, Masaharu Nishimura, Hiroyuki Suzuki, Hirotoshi Dosaka-Akita, Hiroshi Isobe
Publikováno v:
Heliyon, Vol 6, Iss 7, Pp e04439- (2020)
Objectives: Few reports have explored clinical biomarkers, including those identified by targeted exome sequencing (TES) of surgically resected small-cell lung cancer (SCLC) and correlation with patient survival. Patients and methods: We collected fo
Externí odkaz:
https://doaj.org/article/9792b861d55a42e2a0ab67b415950c6c
Autor:
Noriaki Sukoh, Osamu Honjo, Yasuyuki Ikezawa, Hisashi Tanaka, Atsushi Nakamura, Ryoichi Honda, Hiroshi Isobe, Gaku Yamamoto, Ryo Morita, Hajime Asahina, Kenichiro Ito, Hirotoshi Akita, Takaaki Sasaki, Nozomu Kimura, Hajime Kikuchi, Keiki Yokoo, Toshiyuki Sumi, Satoshi Oizumi, Toshiyuki Harada, Yuka Fujita, Taichi Takashina, Hirotoshi Dosaka-Akita, Fumihiro Hommura
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports
Scientific Reports
Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line therapy for
Autor:
Hiroshi Saijo, Yoshihiko Hirohashi, Osamu Honjo, Toyohiro Saikai, Naoki Shijubo, Hirotsugu Takabatake, Akihisa Fujita, Yasuhito Honda, Hiroyuki Koba, Hirofumi Chiba, Toshihiko Torigoe
Background Immunotherapy using immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). Although several ICI options are available, the treatment regimen for NSCLC with large tumors (large N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2099abe1da36510ac4c016761c220a7
https://doi.org/10.21203/rs.3.rs-2069469/v1
https://doi.org/10.21203/rs.3.rs-2069469/v1
Autor:
Takuya Inoue, Kenji Akie, Hiroshi Nishihara, Fumiko Sugaya, Chengbo Tan, Masayuki Watanabe, Hayato Mine, Hironori Takagi, Jun Sakakibara-Konishi, Koji Nakamura, Songji Zhao, Yoshinori Minami, Hirotoshi Dosaka-Akita, Hiroshi Yokouchi, Osamu Honjo, Masao Harada, Masaharu Nishimura, Hiroyuki Suzuki, Miho Aoki, Shigeo Yamazaki, Tetsuya Kojima, Naoyuki Okabe, Saki Shimoyama, Hikaru Yamaguchi, Takeo Hasegawa, Akihiro Inano, Yuki Matsumura, Jun Osugi, Hajime Kikuchi, Mika Hoshino, Satoshi Oizumi, Yuki Ozaki, Mitsunori Higuchi, Kei Takamura, Yuka Fujita, Ryuzo Kanno, Takumi Yamaura, Hiroshi Isobe, Toshiyuki Harada, Yutaka Shio, Satoshi Muto, Mitsuro Fukuhara
Publikováno v:
Lung Cancer. 153:134-142
Objectives Delta-like 1 homolog (DLK1) is a non-canonical Notch ligand known to be expressed in several cancers but whose role in lung cancer is not yet fully understood. We sought to confirm DLK1 expression in small-cell lung cancer (SCLC) and non-s